115 related articles for article (PubMed ID: 35822421)
41. Level V Metastasis, a Novel Predicative Factor for Recurrence in N1b Papillary Thyroid Carcinoma.
Wu Y; Li J; Wu X; Dai L
Curr Pharm Des; 2018; 24(5):559-563. PubMed ID: 28990528
[TBL] [Abstract][Full Text] [Related]
42. Comparing the Prognostic Value of the Eighth Edition of the American Joint Committee on Cancer/Tumor Node Metastasis Staging System Between Papillary and Follicular Thyroid Cancer.
van Velsen EFS; Stegenga MT; van Kemenade FJ; Kam BLR; van Ginhoven TM; Visser WE; Peeters RP
Thyroid; 2018 Aug; 28(8):976-981. PubMed ID: 29848239
[TBL] [Abstract][Full Text] [Related]
43. Efficacy and safety of microwave ablation for the treatment of multifocal versus unifocal T1N0M0 papillary thyroid carcinoma: a propensity-matched multicentre retrospective study.
Zhao ZL; Dong G; Wang SR; Liu Y; He JF; Shi LL; Guo JQ; Wang ZH; Cong ZB; Liu LH; Yang BB; Qu CP; Wei Y; Peng LL; Li Y; Lu NC; Wu J; Yu MA
Eur Radiol; 2023 Dec; 33(12):8727-8735. PubMed ID: 37466709
[TBL] [Abstract][Full Text] [Related]
44. Surgeon volume and prognosis of patients with advanced papillary thyroid cancer and lateral nodal metastasis.
Kim HI; Kim TH; Choe JH; Kim JH; Kim JS; Kim YN; Kim H; Kim SW; Chung JH
Br J Surg; 2018 Feb; 105(3):270-278. PubMed ID: 29405275
[TBL] [Abstract][Full Text] [Related]
45. Management of Very Elderly Patients With Papillary Thyroid Cancer: Analysis of Outcomes for Surgery Versus Nonsurgery.
Zhou J; Tan J; Ming J; Guo H; Li X; Zhang N; Huang T
J Surg Res; 2020 Dec; 256():512-519. PubMed ID: 32798999
[TBL] [Abstract][Full Text] [Related]
46. Treatment Outcomes and Risk Factors for Recurrence After Definitive Surgery of Locally Invasive Well-Differentiated Papillary Thyroid Carcinoma.
Kim JW; Roh JL; Gong G; Cho KJ; Choi SH; Nam SY; Kim SY
Thyroid; 2016 Feb; 26(2):262-70. PubMed ID: 26566765
[TBL] [Abstract][Full Text] [Related]
47. Adjuvant external beam radiotherapy for locally invasive papillary thyroid cancer.
Megwalu UC; Orloff LA; Ma Y
Head Neck; 2019 Jun; 41(6):1719-1724. PubMed ID: 30620424
[TBL] [Abstract][Full Text] [Related]
48. Association Between Treatment at High-Volume Facilities and Improved Overall Survival in Soft Tissue Sarcomas.
Venigalla S; Nead KT; Sebro R; Guttmann DM; Sharma S; Simone CB; Levin WP; Wilson RJ; Weber KL; Shabason JE
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):1004-1015. PubMed ID: 29485042
[TBL] [Abstract][Full Text] [Related]
49. Impact of Age on the Prognosis of Papillary Thyroid Carcinoma.
Sun Y; Dai W; Liang Y; Xia N
Arch Iran Med; 2020 Mar; 23(3):169-174. PubMed ID: 32126785
[TBL] [Abstract][Full Text] [Related]
50. Influence of facility volume on long-term survival of patients undergoing esophagectomy for esophageal cancer.
Patel DC; Jeffrey Yang CF; He H; Liou DZ; Backhus LM; Lui NS; Shrager JB; Berry MF
J Thorac Cardiovasc Surg; 2022 Apr; 163(4):1536-1546.e3. PubMed ID: 34247867
[TBL] [Abstract][Full Text] [Related]
51. Case volume regionalization and volume-based outcome differences in cutaneous head and neck melanoma.
Roman KM; Torabi SJ; Goshtasbi K; Kuan EC; Tjoa T; Haidar YM
Head Neck; 2022 Nov; 44(11):2428-2436. PubMed ID: 35903986
[TBL] [Abstract][Full Text] [Related]
52. Comparison of clinicopathological features and prognosis of papillary thyroid carcinoma and microcarcinoma: A population-based propensity score matching analysis.
Qian B; Hu L; Zhang S; Zhu J; Mei L; Huang T; Qu X
Front Endocrinol (Lausanne); 2022; 13():944758. PubMed ID: 35992148
[TBL] [Abstract][Full Text] [Related]
53. Lymph node ratio as a tool to stratify patients with N1b papillary thyroid cancer.
Luo Z; Hei H; Qin J; Zheng C; Gong W; Zhou B
Langenbecks Arch Surg; 2023 Aug; 408(1):315. PubMed ID: 37584830
[TBL] [Abstract][Full Text] [Related]
54. Association of adjuvant radioactive iodine therapy with survival in node-positive papillary thyroid cancer.
Sun Y; Gong J; Guo B; Shang J; Cheng Y; Xu H
Oral Oncol; 2018 Dec; 87():152-157. PubMed ID: 30527231
[TBL] [Abstract][Full Text] [Related]
55. The association between facility case volume and overall survival in patients with metastatic renal cell carcinoma in the targeted therapy era.
Chen YW; Ornstein MC; Wood LS; Allman KD; Martin A; Beach J; Gilligan T; Garcia JA; Rini BI
Urol Oncol; 2018 Oct; 36(10):470.e19-470.e29. PubMed ID: 30131292
[TBL] [Abstract][Full Text] [Related]
56. Radiation Facility Volume and Survival for Men With Very High-Risk Prostate Cancer Treated with Radiation and Androgen Deprivation Therapy.
Sebastian N; Goyal S; Liu Y; Janopaul-Naylor JR; Patel PR; Dhere VR; Hanasoge S; Shelton JW; Godette KD; Jani AB; Hershatter B; Fischer-Valuck B; Patel SA
JAMA Netw Open; 2023 Aug; 6(8):e2327637. PubMed ID: 37552479
[TBL] [Abstract][Full Text] [Related]
57. Lymphocyte-Monocyte Ratio Significantly Predicts Recurrence in Papillary Thyroid Cancer.
Yokota M; Katoh H; Nishimiya H; Kikuchi M; Kosaka Y; Sengoku N; Watanabe M; Yamashita K
J Surg Res; 2020 Feb; 246():535-543. PubMed ID: 31711613
[TBL] [Abstract][Full Text] [Related]
58. A comparative analysis of treatment efficacy in intermediate-risk thyroid cancer.
Abiri A; Nguyen T; Goshtasbi K; Torabi SJ; Kuan EC; Armstrong WB; Tjoa T; Haidar YM
Eur Arch Otorhinolaryngol; 2023 May; 280(5):2525-2533. PubMed ID: 36651960
[TBL] [Abstract][Full Text] [Related]
59. A comparison of the 7th and 8th editions of the AJCC staging system in terms of predicting recurrence and survival in patients with papillary thyroid carcinoma.
Nam SH; Bae MR; Roh JL; Gong G; Cho KJ; Choi SH; Nam SY; Kim SY
Oral Oncol; 2018 Dec; 87():158-164. PubMed ID: 30527232
[TBL] [Abstract][Full Text] [Related]
60. Differences in the Recurrence and Survival of Patients with Symptomatic and Asymptomatic Papillary Thyroid Carcinoma: An Observational Study of 11,265 Person-Years of Follow-Up.
Kim SH; Roh JL; Gong G; Cho KJ; Choi SH; Nam SY; Kim SY
Thyroid; 2016 Oct; 26(10):1472-1479. PubMed ID: 27457917
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
